Biography

Delaine Smith is the Chief Executive Officer of the Australasian Leukaemia & Lymphoma Group (ALLG). Delaine believes strongly in the advancement of new treatments through sound evidence.

The ALLG is a cooperative trial group representing over 800 member haematologists, researchers, scientist, nurses from across Australia and New Zealand.  In her role at the ALLG Delaine has assisted the ALLG members to achieve a fully independent research framework which has included activities such as the appointment of a Board of Directors in 2010, the establishment of a stand-alone GCP compliant clinical trial operations service, and the growth of the organisation from a $1.5m FY08 operating budget to over $4m operating budget in FY20. Delaine has supported ALLG members with a strong and steady academic clinical trial office and business team resulting in members being able to offer 3-4 new trials a year to their patients, with a constant of 18-22 trials open to recruitment at any one time. The ALLG recruits anywhere between 280-330 patients per year to clinical trials and an additional 300-350 per year to the acute leukaemia clinical registry.

Delaine is a member of the CCTG Executive Officer Network, and former Chair. Delaine is a key contributor to Australia’s National Blood Cancer Taskforce as a member of the Steering Committee and as a leader of one of the three Working Groups.

In her role as CEO of the ALLG she shares a vision to support the scientific research community towards finding new treatments and improving outcomes for patients with haematological disorders.

Featured